Efficacy and Safety of Oral PCSK9 Inhibitor, MK-0616 in the Treatment of Hypercholesterolemia - report from ACC2023

Professor Eliot Brinton, the President, Utah Lipid Center, Salt Lake City explains the results of the research led by Professor Christie Ballantyne, that found MK-0616, an oral PCSK inhibitor, substantially reduced LDL Cholesterol by over 60% at 8 weeks in a clinical trial presented at the American College of Cardiology's 72nd Annual Scientific Session & Expo in New Orleans. Video: https://medicaldigest.org/scientific-contents/interview:efficacy-and-safety-oral-pcsk9-inhibitor-mk-0616-treatment-hypercholesterolemia